ASH Meeting on Hematologic Malignancies

ASH Meeting on Hematologic Malignancies

Coverage of ASH’s newest clinical meeting, featuring top experts in hematologic malignancies discussing the latest developments in clinical care and answering challenging patient care questions

Studies Examine Link Between Ibrutinib and Atrial Fibrillation in Patients With Leukemia and Lymphoma

Though drug ibrutinib has been linked to the development of atrial fibrillation (AF) and atrial flutter (AFl), with an observed incidence of AF among...

A Look at Patient Outcomes in Overlapping Multiple Myeloma and Chronic Lymphocytic Leukemia

Though multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) have overlapping epidemiologic features and originate from mature B cells, the simultaneous occurrence of both...

Improving Risk Stratification in Standard-Risk Myeloma Patients: Age, Bone Marrow Involvement Independently Predict Survival

Though the field of multiple myeloma (MM) has seen many advances in treatment in the past two years – including three new drug approvals...

Adolescents and Minority Groups Underrepresented in Cancer Clinical Trials

Adolescent and young adult (AYA) patients, defined as those between the ages of 15 and 29 years, and non-white patients are often under-represented in...

TP53 Mutation Associated With Poor, But Varied, Outcomes in Myelodysplastic Syndromes

The TP53 mutation, a common molecular abnormality in myeloid malignancies such as myelodysplastic syndromes (MDS), is associated with poor outcomes; however, it is unclear...

Shared-Care Model of Post-Consolidation Care Reduces Travel Burden for AML Patients

In Canada, investigators have been evaluating a shared-care model for acute myeloid leukemia (AML) post-consolidation supportive therapy. The collaborative program permits patients to visit...

Ibrutinib + Bendamustine/Rituximab in Patients with Previously Treated CLL/SLL

The combination of ibrutinib and bendamustine/rituximab (BR) was well-tolerated and did not significantly affect the safety profile of BR in patients with previously treated...

Microtransplantation: A Better Option for AML Patients Without an HLA-Identical Donor?

The optimal therapy for patients with intermediate-risk acute myeloid leukemia (AML) in first complete remission is uncertain. Microtransplantation, the practice of infusing patients with...

Daratumumab Has Favorable Safety Profile in Relapsed/Refractory Multiple Myeloma Patients

For relapsed/refractory multiple myeloma (MM) patients treated with the anti-CD38 monoclonal antibody daratumumab, management of infusion-related reactions (IRRs) required temporary slowing or stopping of...

Researchers Identify Markers of Relapse in Post-Transplant Multiple Myeloma Patients

Results from an analysis presented at the 2015 ASH Meeting on Hematologic Malignancies confirm that T-cell exhaustion and senescence (occurring when T cells are...
Advertisement

Current Issue

September 2017, Volume 3, Issue 11

This issue features a look at efforts to include individuals with intellectual and developmental disabilities in clinical research, our new "How I Treat In Brief" section, and more.